Northeast Pharmaceutical Group Co., Ltd. specializes in the production and marketing of pharmaceutical ingredients and preparations. The group's products include antibiotics, vitamins, cardiovascular treatments, anesthetics, medical plants, etc. China accounts for 86.3% of net sales.

Employees

5,727

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
29/06/26	CN¥4.400	+4.76%	16,729,028
26/06/26	CN¥4.200	-3.67%	8,731,108
25/06/26	CN¥4.360	-1.58%	12,123,151
24/06/26	CN¥4.430	-1.34%	12,028,567
23/06/26	CN¥4.490	+2.05%	12,633,539

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 29/06/2026			5-day change	1st Jan Change
4.400 ^CNY	+4.76%		0.00%	-15.71%

06-16	Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for 2025, Payable on 23 June 2026	CI
04-27	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	6.05B 890M 779M 719M 672M 1.26B 84.15B 1.29B 8.66B 3.34B 41.52B 3.34B 3.27B 144B	P/E 2024	18.2x	P/E 2025	29x
Enterprise Value	4.56B 671M 587M 542M 506M 953M 63.42B 975M 6.53B 2.52B 31.29B 2.52B 2.46B 109B	EV / Sales 2024	0.62x	EV / Sales 2025	0.84x
Free-Float	39.04%	Yield 2024	1.9%	Yield 2025	1.05%

06-16	Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for 2025, Payable on 23 June 2026	CI
04-27	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-03	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-02	Northeast Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 23, 2026	CI
28/10/25	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
09/10/25	Northeast Pharmaceutical Unit Gets Clinical Trial Approval for Glioma Treatment	MT
08/09/25	Northeast Pharmaceutical Appoints CFO	MT
02/09/25	Northeast Pharmaceutical CFO Resigns	MT
27/08/25	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
05/06/25	Northeast Pharmaceutical Gets Nod to Market Antiobiotic in Europe	MT
28/04/25	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
26/04/25	Northeast Pharmaceutical Group Co., Ltd. Announces Directorate Appointments	CI
26/04/25	Northeast Pharmaceutical Group Co., Ltd. Approves Cash Dividend on (A Shares) for 2024, Payable on 23 June 2025	CI

1 day	+4.76%
Current month	-5.58%
1 month	-5.58%
3 months	-15.71%
6 months	-16.19%
Current year	-15.71%

Northeast Pharmaceutical Group Co., Ltd. Stock

Stocks

000597

CNE0000009G0

Pharmaceuticals

Valuation: Northeast Pharmaceutical Group Co., Ltd.

Chart: Northeast Pharmaceutical Group Co., Ltd.

Latest news : Northeast Pharmaceutical Group Co., Ltd.

Press Releases: Northeast Pharmaceutical Group Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Northeast Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	4.09	4.67
1 month	4.09	4.73
Current year	4.09	5.73
1 year	4.09	6.68
3 years	3.72	6.69
5 years	3.72	9.3
10 years	3.72	9.3

Manager	Title	Age	Since
Yong Gang Cai CEO	Chief Executive Officer	46	21/01/2025
Xin Li DFI	Director of Finance/CFO	46	06/09/2025
Dong Sheng Yan IRC	Investor Relations Contact	42	01/07/2024

Director	Title	Age	Since
Kai Zhou CHM	Chairman	62	21/01/2025
Xin Hua Ao BRD	Director/Board Member	62	18/07/2018
Cheng Ren Huang BRD	Director/Board Member	62	18/07/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/06/22	Zhengwei	Buy		36,000	0.0027%
26/05/22	Yan Liu	Buy	Executive/Senior Manager	100	0.0000%
25/05/22	Zhengwei	Buy		28,100	0.0021%

	2024	2025
Net sales	7.5B 1.1B 966M 892M 833M 1.57B 104B 1.6B 10.74B 4.14B 51.48B 4.14B 4.05B 179B	7.07B 1.04B 911M 841M 786M 1.48B 98.39B 1.51B 10.12B 3.91B 48.54B 3.91B 3.82B 169B
Net income	410M 60.29M 52.79M 48.73M 45.51M 85.67M 5.7B 87.62M 586M 226M 2.81B 226M 221M 9.76B	260M 38.26M 33.5M 30.92M 28.88M 54.36M 3.62B 55.6M 372M 144M 1.78B 144M 141M 6.2B
Net Debt	-2.88B -423M -370M -342M -319M -601M -40B -615M -4.11B -1.59B -19.73B -1.59B -1.55B -68.5B	-1.49B -219M -192M -177M -166M -312M -20.73B -319M -2.13B -823M -10.23B -823M -805M -35.51B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHEAST PHARMACEUTICAL GROUP CO., LTD.	+4.76%	0.00%	-14.56%	-14.40%	924M
ELI LILLY AND COMPANY	-1.75%	+9.73%	+55.83%	+159.02%	1,097B
JOHNSON & JOHNSON	-1.10%	+7.21%	+67.80%	+54.85%	622B
ABBVIE INC.	-1.01%	+7.80%	+36.34%	+87.84%	449B
ROCHE HOLDING AG	-1.79%	+6.34%	+29.51%	+24.01%	334B
ASTRAZENECA PLC	-0.52%	+5.02%	+41.03%	+26.57%	294B
NOVARTIS AG	+0.51%	+3.10%	+32.31%	+41.38%	286B
NOVO NORDISK A/S	+0.73%	+2.89%	-27.97%	-42.40%	213B
AMGEN INC.	-0.30%	+4.00%	+29.25%	+62.55%	195B
GILEAD SCIENCES, INC.	-1.00%	+0.35%	+13.19%	+62.83%	157B
Average	-0.14%	+5.91%	+26.27%	+46.23%	364.77B
Weighted average by Cap.	-1.00%	+8.72%	+41.86%	+79.13%